Updates are available Correction dated 2022-04-12

Article History

Accepted: 9 November 2021

First Online: 29 November 2021

Change Date: 12 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-022-00881-2

Declarations

:

: The study was supported by funding from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; all authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication. Open Access funding was also provided by Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

: Toshio Shimizu has received grants/grants pending from Takeda Pharmaceutical Company Limited, Novartis, Eli Lilly, Daiichi-Sankyo, Bristol-Myers Squibb, Eisai, AbbVie, AstraZeneca, Incyte, Pfizer, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, and Five Prime outside the submitted work, and consulting fees or honorarium from Takeda Pharmaceutical Company Limited and Daiichi Sankyo. Yasutoshi Kuboki has received grants/grants pending from Amgen, Takeda Pharmaceutical Company Limited, AstraZeneca, Ono Pharmaceutical Company Limited, Taiho Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, AbbVie, GSK, Chugai Company Limited, Daiichi-Sankyo, and Genmab K.K., consulting fees or honorarium from Takeda Pharmaceutical Company Limited, and payment for lectures including services on speakers bureau from Taiho, Sanofi, Bayer Yakuhin, and Ono Pharmaceutical Company Limited. Chia-Chi Lin has received consulting fees from Blueprint Medicines, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, and Novartis, honorarium from Eli Lilly, Novartis, and Roche, and travel support from BeiGene and Eli Lilly. Kan Yonemori has received consulting fees or honorarium from Takeda Pharmaceutical Company Limited, Eisai, Chugai, AstraZeneca, Elli Lilly, Pfizer, Novartis, and Ono Pharmaceutical Company Limited. Tomoko Yanai is employed by Takeda Pharmaceutical Company Limited. Douglas V. Faller is employed by Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. lwona Dobler is employed by Millennium Pharmaceuticals, Inc. and has stock/stock options with Takeda Pharmaceutical Company Limited. Neeraj Gupta is employed by Millennium Pharmaceuticals, Inc. Farhad Sedarati is employed by Millennium Pharmaceuticals, Inc. Kyu-pyo Kim has no conflict of interests to declare.

: The study was conducted in accordance with the Declaration of Helsinki, the International Council on Harmonisation Guideline for Good Clinical Practice, and applicable local or regional regulatory requirements. Institutional review boards approved all aspects of the study.

: All patients who participated in the study provided written informed consent.

: Not applicable.

: The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results reported in this article, will be made available within three months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.

: Not applicable.

: Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, lwona Dobler, and Neeraj Gupta contributed to the acquisition, analysis, or interpretation of data for the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Kan Yonemori contributed to the conception or design of the work; contributed to the acquisition, analysis, or interpretation of data for the work; revised the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Tomoko Yanai contributed to the acquisition, analysis, or interpretation of data for the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Douglas V. Faller contributed to the conception or design of the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Farhad Sedarati contributed to the conception or design of the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Kyu-pyo Kim contributed to the acquisition, analysis, or interpretation of data for the work; revised the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.